Human erythrocyte (RBC)

Human erythrocytes, or red blood cells (RBCs), are the most abundant cellular component of blood, specialized for the efficient transport of oxygen and carbon dioxide between the lungs and systemic tissues. They are characterized by a unique biconcave shape and the absence of a nucleus and most organelles at maturity, which allows for a high concentration of the oxygen-binding protein hemoglobin (StatPearls, 2023). Beyond gas exchange, erythrocytes contribute significantly to the regulation of blood pH through the carbonic anhydrase reaction and play a role in vascular signaling via nitric oxide metabolism. In clinical pharmacology, erythrocytes are central to the pathology of various hematological disorders; for example, in sickle cell disease, the polymerization of abnormal hemoglobin S causes RBC deformation, leading to anemia and vascular occlusion (NIH, 2023). While the erythrocyte itself is a cellular entity and not a single molecular target, specific components such as hemoglobin or pyruvate kinase are the focus of therapeutic interventions like Voxelotor or Mitapivat. Furthermore, erythrocytes are increasingly utilized in biotechnology as biocompatible vehicles for long-circulating drug delivery (PubMed, 2021).

Other names

Red blood cellHematidErythrocyte

Modulation of hemoglobin oxygen affinity, induction of fetal hemoglobin (HbF), stimulation of erythropoiesis in progenitor cells, and activation of erythrocyte pyruvate kinase (StatPearls, 2023; FDA, 2019).